Hengrui Pharmaceutical announced that its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-2906 injections and will conduct clinical trials in the near future. SHR-2906 injection is a therapeutic biological product independently developed by the company. It is expected to have a synergistic effect in reducing energy intake, promoting energy consumption, etc., regulating carbohydrate metabolism and controlling body weight, while improving the metabolic environment in the body, and is expected to have clinical efficacy in treating overweight and obesity. Currently, no similar drugs have been approved for marketing at home or abroad. Up to now, the total R&D investment for SHR-2906 injection-related projects is about 17.06 million yuan.

Hengrui Pharmaceutical announced that its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for SHR-2906 injections and will conduct clinical trials in the near future. SHR-2906 injection is a therapeutic biological product independently developed by the company. It is expected to have a synergistic effect in reducing energy intake, promoting energy consumption, etc., regulating carbohydrate metabolism and controlling body weight, while improving the metabolic environment in the body, and is expected to have clinical efficacy in treating overweight and obesity. Currently, no similar drugs have been approved for marketing at home or abroad. Up to now, the total R&D investment for SHR-2906 injection-related projects is about 17.06 million yuan.